Key result
Sulfonylureas improve insulin secretion in NIDDM but carry long-lasting hypoglycemia risks in elderly patients.
Why the study?
How should sulfonylureas be used in patients with non-insulin-dependent diabetes mellitus?
How should sulfonylureas be used in patients with non-insulin-dependent diabetes mellitus?
Sulfonylureas remain a useful treatment for non-insulin-dependent diabetes mellitus when initiated early at the lowest possible dose, preferably using short-acting agents to minimize the risk of severe hypoglycemia.
Supports short-acting sulfonylureas at low doses to limit hypoglycemia in elderly patients; leaves open optimal long-term strategies.
Although controversies remain as to the usefulness of sulfonylureas, most evidence is in favor of their use in many if not patients with non-insulin-dependent diabetes mellitus. When used properly, sulfonylureas improve insulin secretion and action, and these effects may be maintained for years. If combined with hypocaloric dietary regulation, rapid- and short-acting sulfonylureas may help patients reach and maintain euglycemia without provoking chronic hyperinsulinemia or weight increase. There is no evidence that sulfonylurea treatment causes beta-cell exhaustion; instead, the antihyperglycemic effect helps improve beta-cell function. Sulfonylurea "failures" are often dietary failures or may be due to late introduction of these drugs, i.e., when beta-cell function is already attenuated. Desensitization of the insulinotropic effect of sulfonylureas may occur but might be avoided by discontinuous (less than 24 h/day) sulfonylurea exposure, i.e., once-daily administration of a short-acting sulfonylurea in a moderate dose. The most important adverse effect of sulfonylureas is long-lasting hypoglycemia, which may lead to permanent neurological damage and even death. This is mainly seen in elderly subjects who are exposed to some intercurrent event, e.g., acute energy deprivation or a drug interaction, i.e., aspirin. Long-acting sulfonylureas may be more likely to promote long-lasting hypoglycemia. The dose-response relationships of sulfonylureas have been poorly investigated, and sulfonylurea therapy should always be initiated and maintained at the lowest possible dose.
No takes yet. Share an insight, caveat, or question.
Melander et al. (1990) conducted a review in non-insulin-dependent diabetes mellitus. Sulfonylureas was evaluated. Sulfonylureas improve insulin secretion and action in non-insulin-dependent diabetes mellitus, though they carry a risk of long-lasting hypoglycemia, especially in elderly patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: